Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Frontiers in Drug DiscoveryOpen Access

Advancing histone deacetylase 6 (HDAC6) as a promising therapeutic target for Alzheimer’s disease: from molecular insights to clinical prospects

View Full Paper
Ask AI
Bookmark
Share

Authors

WZWei ZhangYZYueyang ZhangYWYanli Wang

Discussion

Loading...

Member takes

Overview

This review discusses HDAC6 as a target for Alzheimer's disease, suggesting its potential to improve cognitive deficits related to β-amyloid and tau protein.

Key Points

  • HDAC6 inhibitors may improve Aβ clearance and reduce tau aggregation in Alzheimer's disease models.
  • Deficiency of HDAC6 has been shown to ameliorate cognitive deficits in mouse models of Alzheimer's.
  • Future research must leverage multimodal approaches to discover potent HDAC6-selective inhibitors.
  • The urgent need for effective AD treatments highlights the potential of HDAC6 inhibitors as promising therapeutics.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/68c23abeb210217d6478254ahttps://doi.org/10.3389/fddsv.2025.1662691
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1HDAC6 Inhibition Reduces Seeded Tau and α-Synuclein Pathologies in Primary Neuron Cultures and Wild-type Mice2025
  2. 2Histone Deacetylases in Neurodegenerative Diseases and Their Potential Role as Therapeutic Targets: Shedding Light on Astrocytes2025
  3. 3HDACs in the Brain: From Chromatin Remodeling to Neurodegenerative Disease2025
  4. 4Discovery of a Promising Hydroxyamino-Piperidine HDAC6 Inhibitor via Integrated Virtual Screening and Experimental Validation in Multiple Myeloma2025
  5. 5Design and evaluation of highly selective HDAC6 inhibitors derived from the natural product tryptoline2025